source
- FDA approves Regeneron's Livsayis, first RNAi therapy for generalized myasthenia gravisThe Food and Drug Administration approved Regeneron's Livsayis, an RNA interference drug for generalized myasthenia gravis, marking the company's first marketed RNAi therapy. The drug, originally…
- Sanofi's Infilbray receives first U.S. approval for treating neurological symptoms of Gaucher diseaseSanofi announced that the U.S. Food and Drug Administration has granted approval for Infilbray, a therapy aimed at the neurological manifestations of Gaucher disease, a rare genetic disorder. The…